Podcasts about axspa

In this episode, we examine the evaluation of pain in patients with chronic inflammatory arthritis, with particular attention to spondyloarthritis and its clinical overlap with fibromyalgia. We explore why some patients continue to report persistent pain despite well-controlled inflammation, and the importance of distinguishing between active inflammatory disease and centralized pain syndromes such as fibromyalgia. Join us as we unpack the diagnostic nuances that can significantly impact patient care. 

Join Dr Sofia Ramiro and cohosts Professors Atul Deodhar, Hideto Kameda, and Xenofon Baraliakos for the latest episode of the discussing axSpA podcast on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in axSpA. In this episode, our faculty discusses two papers: the first assesses switching to secukinumab or cycling with other TNF inhibitors, and the second investigates long-term safety of bimekizumab in adult patients with axSpA or PsA.

Join Gozde and Oliver as they talk with Prof. Denis Poddubnyy about the ASAS consensus definition of difficult-to-manage axSpA.Get a behind-the-scenes look at how this definition was developed, the challanged faced, and what it means for clinical practice and research.

In this episode, we're joined by Dr. Atul Deodhar, a leading expert in the field of Axial Spondyloarthritis (AxSpA). Dr. Deodhar shares insights from his groundbreaking research on the pathophysiology, diagnosis, and management of AxSpA, particularly focusing on the efficacy and safety of IV secukinumab. We dive deep into his study, INVIGORATE-1, exploring the methods behind it, including the use of Interactive Response Technology, and the primary and secondary endpoints that shed light on this treatment's impact. We also discuss the latest data on patient preferences for subcutaneous versus intravenous immunomodulators and the implications of these findings. Tune in for an informative and engaging conversation that blends cutting-edge science with thoughtful reflections on patient care. 

In this episode, we dive into the cutting-edge advancements presented by Dr. Christopher T. Ritchlin at Convergence 2024, where he shed light on the promising research set to transform the field of rheumatology. Join us as we break down key insights from one of the field's leading experts, exploring the future of precision medicine, the role of TRBV9 cells in axSpA, the impact of sex differences on PsA, and the potential of urinary biomarkers in Lupus Nephritis. Tune in for a fascinating discussion on what's next in rheumatology. 

Join Dr Sofia Ramiro and cohosts Professors Atul Deodhar, Hideto Kameda, and Xenofon Baraliakos for the latest episode of the discussing axSpA podcast on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest updates in axSpA. In this episode, our faculty discusses two papers both focusing on the long-term safety and efficacy of Bimekizumab in axSpA patients with 5-year results from the BE-AGILE study and its OLE, and the 2-year results from BE-MOBILE 1 and 2.

Listen in as rheumatology experts Alexis Ogdie, MD, MSCE, and Julia Swafford, PA-C, DFAAPA, discuss emerging therapies and strategies in managing patients with axial spondyloarthritis or psoriatic arthritis, including:The current treatment landscape (eg, small molecules, biologics)Risk factors to consider when prescribing JAK inhibitorsKey considerations regarding comorbidities, especially in addressing depression, anxiety, or social ideation Nonpharmacologic options to improve treatment outcomesShared decision-making strategies to enhance patients' investment in their carePresenter:Alexis Ogdie, MD, MSCEDirector, Penn Psoriatic Arthritis and Spondylarthritis ProgramDirector, Penn Center for Clinical Epidemiology and BiostatisticsUniversity of PennsylvaniaPhiladelphia, PennsylvaniaJulia Swafford, PA-C, DFAAPAPresident of SPARBronson Battle Creek Rheumatology SpecialistsBattle Creek, MichiganLink to full program:https://bit.ly/4gkTzSv

Listen in as rheumatology experts Alexis Ogdie, MD, MSCE, and Julia Swafford, PA-C, DFAAPA, discuss emerging therapies and strategies in managing patients with axial spondyloarthritis or psoriatic arthritis, including:The current treatment landscape (eg, small molecules, biologics)Risk factors to consider when prescribing JAK inhibitorsKey considerations regarding comorbidities, especially in addressing depression, anxiety, or social ideation Nonpharmacologic options to improve treatment outcomesShared decision-making strategies to enhance patients' investment in their carePresenter:Alexis Ogdie, MD, MSCEDirector, Penn Psoriatic Arthritis and Spondylarthritis ProgramDirector, Penn Center for Clinical Epidemiology and BiostatisticsUniversity of PennsylvaniaPhiladelphia, PennsylvaniaJulia Swafford, PA-C, DFAAPAPresident of SPARBronson Battle Creek Rheumatology SpecialistsBattle Creek, MichiganLink to full program: bit.ly/4gkTzSv

Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar, and Xenfon Baraliakos to discuss a recent study on the efficacy and safety of upadacitinib in patient with ankylosing spondylitis.

In this episode, we explore the findings of a groundbreaking study analyzing opioid treatment trends for adults with and without systemic autoimmune and inflammatory rheumatic diseases (SARDs) from 2006 to 2019. The study, based on national data from the United States, sheds light on how individuals with conditions like rheumatoid arthritis, lupus, and ankylosing spondylitis are impacted by opioid use compared to the general population. 

A New ACR Anti IL-17 on Entheseal Biopsy in PsA axSpA: Impact of TNF and IL-17 in Patients with Prior TNF Exposure Best Things I Saw Today in PsA Cycling vs Switching after TNFi Failure in axSpA Improvements in Pain and Fatigue in Bimekizumab Long-term Safety Profile of Bimekizumab in axSpA and PsA Sonelokimab in PsA: Phase 2 Data Treating SpA

A New ACR Assessing ASAS Criteria: CLASSIC Study Results Assessment and management of axSpA Assessment of axSpA Carotid Doppler Ultrasound Screening in Axial SpA Cycling vs Switching after TNFi Failure in axSpA Defining Difficult to Manage axSpA Difficult to manage AxSpA DISH in SpA Gender Differences in AxSpA Highlights in axSpA Hot Topics in axSpA Long-term Safety Profile of Bimekizumab in axSpA and PsA Machine Learning for Predicting Flares in axSpA Precision Immunotherapy in Axial SpA PREDICT-SpA: Evaluating the influence of gender on disease assessment tools Treating SpA What is a Positive MRI in Spondyloarthritis? axSpA: Impact of TNF and IL-17 in Patients with Prior TNF Exposure

A New ACR Apremilast Benefits and Risks in PsA Best Things I Saw Today in PsA Bimekizumab in PsA Showed Sustained Reductions in Disease Impact Biologic Monotherapy vs Combination with cDMARDs in PsA Do TNFis and JAKis Prevent Cancer!? Improvements in Pain and Fatigue in Bimekizumab Long-term Safety Profile of Bimekizumab in axSpA and PsA Potential Impact of Weight Loss Drugs in Rheumatic Diseases Proposed ACR Guidance for Use of MSUS in Psoriatic Arthritis PsA Potpourri PsA Ultrasound Updates PsA: Impact of Sex Sex Differences in Psoriatic Arthritis The Psoriatic March: PsA before PsO Apremilast in PsA: Results from Mosaic Trial Anti IL-17 on Entheseal Biopsy in PsA

Control RA, Build Stronger Bones:Dr. Jiha Lee talks with Dr. Rachel Elam  Hold or continue JAKi and IL-17 when receiving COVID boosters?:Dr. Bella Mehta Long-term Safety Profile of Bimekizumab in axSpA and PsA:Dr. Philip Mease Navigating Rheumatology Care in Humanitarian Crisis Settings:Dr. Antoni Chan talks with Dr. Martha Dhzhus RA Roundup: Is LDA Inappropriate? What about Statins for JAKs?:Dr. Eric Dein  Sex Differences in Psoriatic Arthritis:Dr. Catherine Bakewell Single v Double Lung Transplants for Disease-related ILD:Dr. Eric Dein talks with Dr. Harry Hurley Sonelokimab in PsA: Phase 2 Data:Dr. Philip Mease Treating SpA:Dr. Marina Magrey

Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, and Atul Deodhar to discuss a recent study on the efficacy and safety of IV secukinumab in patient with active axSpA.

Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar, and Xenofon Baraliakos to discuss a recent study on the incidence of uveitis in patients with axSpA that were treated with bimekizumab.

Xenofon Baraliakos, MD, PhD / Philip Helliwell, MD, PhD - Can the Standard of Care Be Elevated in Spondyloarthropathies? Key Learnings From Rheumacensus Initiatives in PsA and axSpA

Xenofon Baraliakos, MD, PhD / Philip Helliwell, MD, PhD - Can the Standard of Care Be Elevated in Spondyloarthropathies? Key Learnings From Rheumacensus Initiatives in PsA and axSpA

Tune in this week for the final episode of our three part AxSpA series. Dr Moorthy covers everything from exercise to etanercept, and gives all of us yet another good reason to go swimming!

Join us for the latest axSpA podcast brought to you by the Immune- ediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda and Xenofon Baraliakos to discuss the results of a Phase 3 trial on upadacitinib in nr-axSpA and the clinical outcomes of certolizumab pegol treatment in nr-axSpA stratified by baseline MRI and CRP status.

Join us for part 2 of our 3 part AxSpA series! Dr Moorthy goes through the key investigations he orders for his AxSpA patients, and tells us exactly what information is required to make an AxSpA diagnosis!

Join Dr Sofia Ramiro, Professor Rieke Alten, and Associate Professor Laura Coates as they review their top sessions in RA, PsA, and axSpA from EULAR 2024, providing insight into how these data will shape clinical practice going forward.

Dr. Bella Mehta interviews Dr. Vincenzo Venerito about abstract POS0236 at Eular 2024 in Vienna, Austria.

Dr. Antoni Chan discusses abstract OP0132 presented at Eular 2024 in Vienna, Austria.

Dr. Eric Ruderman discusses abstracts OP0046 and POS0058 presented at Eular 2024 in Vienna, Austria. OP0046 Effect on SI joint structural lesions with ixekizumab POS0058 Effect on SI joint structural lesions with bimekizumab

When disease strikes, time becomes a critical resource our patients cannot afford to waste. For those with axial spondyloarthritis (axSpA), an inordinate amount of time often goes by before a proper diagnosis is made, resulting in delays for crucial treatments to be rendered. The reasons for this delay in diagnosis, particularly among those with axSpA are diverse, complicated and not well-understood. Our guest, Dr. Gregory McDermott, attempted to better understand this diagnostic delay with his study: Factors Associated With Diagnostic Delay in Axial Spondyloarthritis: Impact of Clinical Factors and Social Vulnerability  in hopes that we may begin answering these challenges with solutions.  

Join Dr Sofia Ramiro, Professor Rieke Alten, and Associate Professor Laura Coates as they guide you through their top selections in RA, PsA, and axSpA at EULAR 2024, so that you can better plan your time at what will be a busy and exciting congress.

Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar and Xenofon Baraliakos to discuss the long-term etanercept response in patients with radiographic axSpA and the comparison of tofacitinib and adalimumab in a real-world clinical context.

Recent research indicates that those who suffer from AxSpA may have some hope in protecting against events of Uveitis! Dr. Katie Bechman, first author Incidence of Uveitis in Patients With Axial Spondylarthritis Treated With Biologics or Targeted Synthetics: A Systematic Review and Network Meta-Analysis, explains her team's research findings and how they came to this exciting conclusion! 

This week Dr Arumugam Moorthy explains everything you need to know about the clinical history and examination of AxSpA patients. We cover key points of inflammatory back pain, important extra-articular symptoms and a structured examination for AxSpA patients.

Join our expert panel as they discuss the role of Janus kinase (JAK) inhibitors in the treatment of axial spondyloarthritis (axSpA). Credit available for this activity expires: 4/24/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1000707?ecd=bdc_podcast_libsyn_mscpedu

Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda and Atul Deodhar to discuss the retention rate of secukinumab over two different time periods. Our faculty then move on to discuss another publication, which compares the improvements is sacroiliac joint symptoms across patients with AS and axSpA treated with different DMARDs.

Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar and Xenofon Baraliakos to discuss the risk of acute anterior uveitis across different bDMARDs in patients with AS. Our faculty then move on to discuss another publication, which compares patient-reported outcomes (PROs) and 24-month retention rates between patients with axSpA and PsA that were treated with secukinumab.

Join us for the latest axSpA podcast brought to you by the Immune-mediated Inflammatory Disease forum! This month Dr Sofia Ramiro is joined by Professors Hideto Kameda and Xenofon Baraliakos to discuss the long-term impact of secukinumab treatment on bone-related outcomes and BTMs in r-AxSpA patients over two years. Our faculty then move on to discuss another publication, which presents JAKi treatment recommendations for IMIDs from a two-round modified RAM study with 21 subject matter experts.

Join us for the latest axSpA podcast brought to you by the CSF! This month Dr Sofia Ramiro, consultant rheumatologist and senior researcher at Leiden University Medical Centre and Zuyderland Medical Centre, is joined once again by experts with a wealth of clinical knowledge. Joining her is Hideto Kameda, Professor of Internal Medicine at Toho University as well as Atul Deodhar, Professor of Medicine and Medical Director of Rheumatology Clinics in the Division of Arthritis & Rheumatic Diseases at Oregon Health & Science University in Portland, USA. Also joining this insightful group is Xenofon Baraliakos, Professor of Internal Medicine and Rheumatology at the Ruhr-University in Bochum, and Medical Director of the rheumatology centre Rheumazentrum Ruhrgebiet in Herne, Germany In the first paper discussed, the authors compared the efficacy and safety of bimekizumab with biologic/targeted synthetic disease-modifying antirheumatic drugs in nr-axSpA and AS. Our second paper then goes on to identify distinct clinical clusters based on patient demographics and baseline clinical indicators from the clinical development programme of secukinumab in patients with a variety of rheumatological conditions.

Join Doctor Sofia Ramiro as she is joined by Professors Atul Deodhar and Xenofon Baraliakos to discuss the latest top clinical research in the world of axSpA. In the first paper discussed, the authors evaluated the efficacy and safety of tofacitinib in bDMARD-naïve and TNF-IR AS patients. The second paper presents the results of two parallel clinical trials that investigated the safety and efficacy of bimekizumab.

Join Doctor Sofia Ramiro as she is joined by Professors Atul Deodhar and Xenofon Baraliakos to discuss the latest top clinical research in the world of axSpA. In the first paper discussed, the authors evaluated the efficacy and safety of tofacitinib in bDMARD-naïve and TNF-IR AS patients. The second paper presents the results of two parallel clinical trials that investigated the safety and efficacy of bimekizumab.

Bimekizumab in Active AS_ 5 Year Study Deep Neural Networks and Radiographic Progression in AxSpA Difficult to Treat axSpA From AS Patient to Rheumatologist Imaging Updates in SpA INVIGORATE-1 Study_ IV Secukinumab for Treatment of Active axSpA Monitoring the Effect of Therapy with a...Smart Watch_ Overlap of Inflammatory and Degenerative Features in Radiographic axSpA People with AxSpa Need More Sleep Secukinumab vs. Adalimumab Biosimilar on Radiographic Progression in AxSpA SpA Insights_ New Therapies Teledidactic vs On Campus Training in Musculoskeletal Ultrasound Treatments in SpA Undiagnosed IBD in AxSpA Using Telemedicine to Improve Diagnosis of AxSpA

Professor Hideto Kameda, Professor of Internal Medicine at Toho University in Japan, is joined by Professor Xenofon Baraliakos, Professor of Internal Medicine and Rheumatology at the Ruhr-University in Bochum, and a senior consultant and scientific coordinator of the rheumatology centre Rheumazentrum Ruhrgebiet in Herne, Germany, Dr Sofia Ramiro, consultant rheumatologist and senior researcher at Zuyderland Medical Centre and Leiden University Medical Centre in the Netherlands as well as, Atul Deodhar Professor of Medicine and Medical Director of Rheumatology Clinics in the Division of Arthritis & Rheumatic Diseases at Oregon Health & Science University in Portland, USA, to discuss the safety and efficacy of Upadacitinib. The first paper evaluated the 52-week safety, tolerability, and efficacy of updacitinib in the SELECT-AXIS 2 study in patients with AS and an inadequate response to bDMARDs and the second paper then goes on to describe, via a narrative review, the safety and efficacy of updacitinib in axSpA

What is early-stage knee osteoarthritis? How does it differ from later stage knee osteoarthritis? Learn more on this week's episode with Dr Jean Liew.Dr Jean Liew is an Assistant Professor of Medicine in the Section of Rheumatology at Boston University, where her clinical research currently focuses on knee osteoarthritis and axSpA.RESOURCESA scoping review of how early-stage knee osteoarthritis has been definedCONNECT WITH JEANTwitter: @rheum_catCONNECT WITH USTwitter: @ProfDavidHunter @jointactionorgEmail: hello@jointaction.infoWebsite: www.jointaction.info/podcast Hosted on Acast. See acast.com/privacy for more information.

Dr Sofia Ramiro, consultant rheumatologist and senior researcher at Zuyderland Medical Centre and Leiden University Medical Centre in the Netherlands, is joined by Professor Hideto Kameda, Professor of Internal Medicine at Toho University and Atul Deodhar, Professor of Medicine and Medical Director of Rheumatology Clinics in the Division of Arthritis & Rheumatic Diseases at Oregon Health & Science University in Portland, USA to discuss the Efficacy and Safety of Ixekizumab & Tildrakizumab. In the first paper discussed, it describes the safety and efficacy of ixekizumab treatment in patients with r-axSpA and nr-axSpA for up to 156 weeks. The second study discussed goes on to assess the safety and efficacy of tildrakizumab in patients with active AS.

Join Professor Hideto Kameda, and Dr Sofia Ramiro as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. Our first paper aimed to use mediation modelling to determine whether tofacitinib improved fatigue symptoms directly or indirectly. Our second paper shows that IV-golimumab reduces fatigue symptoms in patients with ankylosing spondylitis.

Join Professors Atul Deodhar, Xenofon Baraliakos, Hideto Kameda, and Dr Sofia Ramiro as they discuss the latest top research in axSpA. In this edition, our Steering Committee members discuss two of the latest papers in the field of axSpA therapeutics, providing their own insights and experience into two very interesting publications. Our first paper aimed to determine when the optimal time to start secukinumab treatment is demonstrated by a significant difference between baseline and post treatment BASDAI scores. Our second paper the goes on to evaluate a case report of a 45-year-old male, with AS, and adalimumab-induced refractory paradoxical palmoplantar pustulosis, after failure of prior secukinumab treatment.

We are finishing up this AxSpA series with a bang! I finally managed to get Dr James Noake behind the microphone to talk about AxSpA in Sport and Exercise Medicine. We discuss the patients that attend his clinic, some of his tips, the challenges that this cohort present and the role of SEM Consultants in assessment/management Find James on twitter HERE Please provide feedback on this podcast HERE Thank you to Novartis for sponsoring this Series of 5 podcasts For more resources CLICK HERE

In the second part of a two-part episode dedicated to non-radiographic axial spondyloarthritis (non-rad AxSpA), our hosts are joined by Amanda Ledford, Director of Policy at UCB, and patient advocate Ricky White, who lives with non-rad AxSpA. Amanda and Ricky discuss the advocacy efforts around helping patients receive a diagnosis and how policy and advocacy play a role in helping patients access affordable treatments. "We're really working to remove barriers to the providers' ability to prescribe the most appropriate therapy to their patients. We feel strongly that decisions about the most appropriate treatment should be made by the health care provider and the patient rather than the insurance company,” says Amanda. Among the highlights in this episode: 2:41: Amanda Ledford shares the importance of using a specific ICD-10 – or diagnosis code – for nr-axSpA, and the challenging journey to get the application for the code creation approved 4:37: “With continuing advocacy from UCB, patient groups, [and] professional societies, a new and specific code for nr-axSpA became effective October 2021,” says Amanda 6:20: “Getting disease codes like [ICD-10] is key for people to get the accurate diagnosis and then get treatment,” says Ricky White 7:09: Ricky provides his insights on the access issues and barriers he and other patients encounter in the U.S. when it comes to getting the medication that works best for them 8:55: Amanda shares the efforts to get affordable and equitable access to care for all patients 9:49: “UCB is working with a coalition of patient groups, including GHLF… to advocate for step therapy override legislation at both the state and federal levels,” says Amanda 10:38: Over 30 states have enacted step therapy override legislation so far 11:24: Amanda discusses treatment affordability and explains the concept of copay accumulators 13:01: “16 states and Puerto Rico have already passed some form of copay accumulator legislation at the state level,” says Amanda 14:25: How individuals and local patient organizations can defend treatment affordability and help pass legislation at the state level 15:17: “GHLF has a 50-State Network where we're active in all 50 states and Puerto Rico and we always encourage advocates to join us and advocate with us whether it's testifying, submitting comment letters, or writing an op-ed about your experience” says Zoe Rothblatt, Associate Director of Community Outreach at GHLF More information here: www.50statenetwork.org Contact Our Hosts Steven Newmark, Director of Policy at GHLF: snewmark@ghlf.org Zoe Rothblatt, Associate Director, Community Outreach at GHLF: zrothblatt@ghlf.org We want to hear what you think. Send your comments in the form of an email, video, or audio clip of yourself to thehealthadvocates@ghlf.org Catch up on all our episodes on our website or on your favorite podcast channel.See omnystudio.com/listener for privacy information.

Treatment Considerations in Axial Spondyloarthritis What Happens after you stop biologics? What lifestyle factors affect TNF inhibitor efficacy in AxSpA? Which is better for AxSpA? IL-17i or TNFi? Women vs. Men: Response to Treatment in Seronegative Arthritis

Breakthrough COVID infection in RMD patients treated with Evusheld Dr. Yuz Yusof talks with Dr. Chris Podgorski at ACR22 Convergence. Lung Involvement in VEXAS Dr. Yuz Yusof and Dr. Marta Casal Moura discusses abstract 1569 presented at ACR22 Convergence.  Abstract 1569: Lung Involvement in VEXAS Syndrome Reproductive health in a post-Roe world Dr. Robert Chao discusses abstract 1673 and L09 presented at ACR22 Convergence.  Abstract 1673: Preconceptional NSAID Treatment Exposure Is Associated with a Significantly Longer Time-to-conception in Women with Spondyloarthritis: Analysis of the Prospective GR2 Cohort Abstract L09: Impact on Access to Methotrexate in the Post-Roe Era Stop Ordering Repeat ANAs! Dr. Kathryn Dao reviews abstracts 1278, 0228, and 0058 presented at ACR22 Convergence. Ultrasound in PsA Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study What Happens after you stop biologics? Dr. Robert Chao discusses abstract 0427 presented at ACR22 convergence.  Abstract 0427: Recapture Rates with Ixekizumab After Withdrawal of Therapy in Patients with Axial Spondyloarthritis: Results at Week 104 from a Randomized Placebo-controlled Withdrawal Study Which is better for AxSpA? IL-17i or TNFi? Dr. Robert Chao discusses abstract L15 presented at ACR22 Convergence.

Can we alter neonatal gut microbiome to prevent spondyloarthritis? Dr Chao discusses Abstract 0868 at the ACR22 Convergence meeting.  Abstract 0868: Spondyloarthritis and Neonatal Factors Affecting the Gut Microbiome JAK vs TNF inhibitor Infections in RA Dr. David Liew discusses abstract 0302 at ACR22 Convergence. Abstract 0302: Risk of Infections Between JAK Inhibitors and TNF Inhibitors Among Patients with Rheumatoid Arthritis Opioid and Neuropathic Use After Initiating btsDMARDs in RA Dr. Julian Segan discusses Abstract 0925 at the ACR22 Convergence meeting. The Dietary Intervention in PsA (DIPSA) StudyDr. Patricia Harkins talks with Professor Lihi Eder about abstract 1007 at the ACR22 Convergence meeting.  Abstract 1007: Metabolic Disorders and Abnormal Dietary Patterns and Their Association with Psoriatic Arthritis Activity: The Dietary Intervention in PsA (DIPSA) Study Treatment Considerations in Axial Spondyloarthritis Dr. Lianne Gensler discusses treatment considerations in Axial SpA. Abstract 0402: Opioid Use and Healthcare Utilization in Adults with PsA and AS Abstract 0388: Incidence Rate and Factors Associated with Fractures Among Older Adults with Ankylosing Spondylitis in the United States Abstract 0544: Bimekizumab Improves Signs and Symptoms, Including Inflammation, in Patients with Active Non-Radiographic Axial Spondyloarthritis: 24-Week Efficacy & Safety from a Phase 3, Multicenter, Randomized, Placebo Controlled Study Abstract 0545: Continuing (Full or Reduced Treatment) versus Withdrawing from Golimumab Treatment in Patients with Non-radiographic Spondylarthritis Who Achieved Inactive Disease: Efficacy and Safety Results from a Placebo-Controlled, Randomized Withdrawal and Retreatment Study (GO-BACK) What lifestyle factors affect TNF inhibitor efficacy in AxSpA? Dr Chao discusses Abstract 1510 at ACR22 Convergence. Abstract 1510: Modifying Lifestyle Factors May Offer the Potential to Enhance the Outcome of Tumour Necrosis Factor Inhibitors in Axial Spondyloarthritis – Data from 14 European Countries    

The truth is there are more than 100 types of arthritis, but not all of them receive the public recognition they deserve, especially non-radiographic axial spondyloarthritis (non-rad AxSpA). In the first of a two-part episode, The Health Advocates are joined by rheumatologist and Head of Immunology Medical at UCB, Dr. Jeff Stark, and patient advocate Ricky White who lives with non-rad AxSpA. Dr. Stark and Ricky discuss the challenges in diagnosis, the advancements in treatment, and the research and advocacy being done to improve the patient journey. "There are barriers for patients around diagnosis and certainly we want for patients with non-radiographic AxSpA to have appropriate treatments,” says Dr. Stark about the challenges patients face, “but there is so much more that can positively impact the journey that patients with this condition undergo." Among the highlights in this episode: 2:05: “There are over 100 types of arthritis and… part of being a patient advocate and a health advocate is letting people know about this information so that number one: people who are undiagnosed may hear about it and recognize symptoms, and number two: to provide a sense of community for those living with the condition as they hear from us and from others,” says Steven Newmark, Director of Policy at GHLF 2:59: Dr. Stark describes what non-radiographic axial spondyloarthritis (non-rad AxSpA) is and what makes it a particularly challenging disease 4:32: There is a misconception that non-rad AxSpA is a milder form of arthritis but for many patients that's just not the case, according to Dr. Stark 5:05: “There's clearly a lot of room for improvement in the journey to diagnosis with non-rad AxSpA,” says Steven Newmark 5:26: Dr. Stark explains how a new diagnostic code was created so that physicians and health care providers in the U.S. can now record a specific diagnosis of non-rad AxSpA in medical records, thus facilitating the journey to diagnosis 8:33: The importance of clinical research regarding non-rad AxSpA explained 11:04: Ricky, who got diagnosed with ankylosing spondylitis in 2010, would now fall under the category of non-rad AxSpA should he be re-diagnosed today -- but that category did not exist in 2010 12:09: Ricky explains his road to diagnosis 14:12: Dr. Stark asks Ricky to describe his journey to finding the right doctor for him and what he looks for in a rheumatologist 17:29: The importance of community in Ricky's journey with non-rad AxSpA and where patients can find support 18:45: Ricky explains how he became an advocate and how he uses his own experience and the knowledge he has accumulated about his condition to help other patients 20:14: Ricky's tips from his own experience of living with his condition 22:27: What our hosts learned from this episode Contact Our Hosts Steven Newmark, Director of Policy at GHLF: snewmark@ghlf.org Zoe Rothblatt, Associate Director, Community Outreach at GHLF: zrothblatt@ghlf.org We want to hear what you think. Send your comments in the form of an email, video, or audio clip of yourself to thehealthadvocates@ghlf.org Catch up on all our episodes on our website or oSee omnystudio.com/listener for privacy information.

Dr. Nimesh Dayal (Orlando Health-Health Central Hospital, Orlando, FL) discusses the relevance of clinical endpoints and guidelines for ax-SpA in clinical practice.